Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details


( Last Updated : February 12, 2020)
Generic Name:
Atezolizumab
Project Status:
Withdrawn
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0171-000
NOC Date:

Details


Strength:
840 mg/14 mL & 1200 mg/20 mL
Tumour Type:
Breast
Indications:
Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
Funding Request:
In combination with nab-paclitaxel for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1, and who have not received prior chemotherapy for metastatic disease. Maintenance TECENTRIQ should be continued until disease progression or unacceptable toxicity.
Review Status:
Withdrawn
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
Clarification:
Hoffmann-La Roche Limited has requested a voluntary withdrawal of the pCODR 10171 Atezolizumab (Tecentriq) for MBC submission.

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.